MARKET

ONCS

ONCS

OncoSec Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.090
+0.010
+0.48%
Closed 16:00 01/17 EST
OPEN
2.080
PREV CLOSE
2.080
HIGH
2.100
LOW
2.020
VOLUME
57.56K
TURNOVER
--
52 WEEK HIGH
9.46
52 WEEK LOW
1.600
MARKET CAP
22.39M
P/E (TTM)
-0.5170
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ONCS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ONCS News

  • Alpha Holdings Comments on OncoSecs Failure to Consider Superior Financing Proposal
  • Business Wire.2d ago
  • OncoSec Board Rejects Alpha Holdings Proposal To Provide $30M In Funding; Says Proposal Is An 'Attempt to Mislead Shareholders into Giving Alpha Control of OncoSec Before Alpha Makes Any Cash Investment and Potentially Without Making Any Investment At All
  • Benzinga.3d ago
  • OncoSec Board Rejects Alpha Holdings "Proposal" and Announces New Special Meeting Date
  • Business Wire.3d ago
  • Alpha Holdings Sends Open Letter to OncoSec Stockholders Answering Questions on Proposed Financing
  • Business Wire.4d ago

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About ONCS

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
More

Webull offers OncoSec Medical Inc (ONCS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.